[144] COPT DEFENSE PROPERTIES SEC Filing

Rhea-AI Filing Summary

COPT Defense Properties (CDP) notice reports a proposed sale of 3,000 common shares through William Blair on the NYSE with an approximate aggregate market value of $91,560. The shares represent a small fraction of the 112,927,513 outstanding shares and are scheduled for sale on 09/17/2025. The filer states the shares were acquired in the open market on 11/30/2017 for cash and that there were no sales in the past three months. The filing includes the standard signature representation that the seller is not aware of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: A small, routine insider sale of 3,000 shares scheduled via broker; not material to company capitalization.

The filing notifies the market of a proposed sale of 3,000 common shares valued at $91,560 to be executed on 09/17/2025 through William Blair on the NYSE. The shares were acquired in the open market on 11/30/2017 and paid in cash. With 112,927,513 shares outstanding, this transaction is immaterial to overall share count and likely will not affect trading liquidity or valuation. The filer reports no related sales in the prior three months, and the notice includes the required representation regarding undisclosed material information.

Compliance/Risk Analyst

TL;DR: Filing meets Rule 144 disclosure elements; no compliance red flags present in provided text.

The Form 144 includes required broker identification, intended sale date, acquisition history, consideration (cash), and a signature representation. Key identifying filer details (CIK/individual contact) are not present in the supplied excerpt, but the substantive sale details are complete: 3,000 shares, acquired 11/30/2017, to be sold 09/17/2025. There are no reported sales in the past three months, which is consistent with a routine Rule 144 notice. No statements in the filing indicate noncompliance or material undisclosed information.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	William Blair & CO 150 N Riverside Plaza Suite 3500 Chicago IL 60666	3000	91560.00	112927513	09/17/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/30/2017	Open Market	Open Market			3000	11/30/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the CDP Form 144 disclose about the proposed sale?

The notice discloses a proposed sale of 3,000 common shares on 09/17/2025 via William Blair on the NYSE with an aggregate market value of $91,560.

How and when were the shares being sold on the Form 144 acquired?

The shares were acquired in the open market on 11/30/2017 and paid for in cash.

Does the filing report recent sales by the same person in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

How large is the sale relative to COPT Defense Properties’ shares outstanding?

The filing shows 112,927,513 shares outstanding; the proposed 3,000-share sale is a de minimis portion of the outstanding shares.

Does the Form 144 include any representation about material information?

Yes. The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed and references Rule 10b5-1 plan language if applicable.